Update: Ultragenyx Shares Fall After Brittle Bone Disease Studies Fail to Achieve Primary Endpoints

MT Newswires Live2025-12-29

(Updates with recent stock price movement in the headline and first paragraph, and adding information on partnership with Mereo in the fifth paragraph.)

Ultragenyx Pharmaceutical's (RARE) shares fell more than 45% in recent Monday trading after the company said its phase 3 studies of setrusumab to treat osteogenesis imperfecta, or brittle bone disease, did not achieve the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates.

Both studies achieved the secondary endpoints of improvements in bone mineral density against comparators, the company said.

Ultragenyx said it is conducting additional analyses across both studies to evaluate its next steps.

The company said it also assessing its planned operations and will implement "significant" expense reductions.

Ultragenyx said it is developing setrusumab in pediatric and young adult patients with osteogenesis imperfecta in partnership with Mereo BioPharma (MREO). Shares of Mereo were down more than 89% in recent trading Monday.

Price: 18.78, Change: -15.42, Percent Change: -45.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment